Haematotoxicity and its impact on therapy continuation during concomitant, adjuvant and extended temozolomide treatment in malignant glioma

H.C. Bock, A. Gutenberg, T. Behm, V. Rohde & A. Giese
Objective: Current treatment standard for malignant glioma is specified by maximal safe resection, radiation therapy and concomitant and adjuvant oral temozolomide chemotherapy. Despite its favourable safety profile dose-related haematotoxic side effects of temozolomide may lead to low haemoglobin, [for full text, please go to the a.m. URL]